Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Theralase Technologies Inc. (V:TLT)

Business Focus: Laser Equipment

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
Company Contact
Address: 41 Hollinger Rd
Tel: 1-416-4478455
IR: See website
Key People
Roger Dumoulin-White
President, Chief Executive Officer, Director
Kristina Hachey
Chief Financial Officer, Director
Arkady Mandel
Chief Scientific Officer, Director
Business Overview
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company's medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.
Financial Overview
For the nine months ended 30 September 2023, Theralase Technologies Inc revenues decreased 13% to C$707K. Net loss decreased 18% to C$3.6M. Revenues reflect Canada segment decrease of 19% to C$557K, International segment decrease of 91% to C$2K. Lower net loss reflects R & d decrease of 40% to C$1.9M (expense), Sales salaries decrease of 25% to C$116K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $40.23M as of Sep 30, 2023
Annual revenue (TTM): $1.03M as of Sep 30, 2023
EBITDA (TTM): -$4.18M as of Sep 30, 2023
Net annual income (TTM): -$4.46M as of Sep 30, 2023
Free cash flow (TTM): -$4.02M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 223,142,675 as of Oct 19, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization